CytoTools AG

  • WKN: A0KFRJ
  • ISIN: DE000A0KFRJ1
  • Land: Deutschland

Nachricht vom 30.09.2021 | 17:04

Annual General Meeting of CytoTools AG votes for dismissal of all Supervisory Board members

DGAP-News: CytoTools AG / Key word(s): AGM/EGM
30.09.2021 / 17:04
The issuer is solely responsible for the content of this announcement.

Annual General Meeting of CytoTools AG votes for dismissal of all Supervisory Board members

Darmstadt, 30 September 2021 - CytoTools AG (ISIN DE000A0KFRJ1), a biotechnology holding company specializing in pharmaceutical and medical products, today held its Annual General Meeting in virtual form. Of the company's share capital of EUR 4,028,000.00, 69.24 percent was represented at the time of voting.

The Annual General Meeting decided on the agenda items to be voted on with the following percentage approval:

Agenda item 2 32.56 percent
Agenda item 3 35.23 percent
Agenda item 4 99.82 percent
Agenda item 5 45.83 percent
Agenda item 6 32.65 percent
Agenda item 7 45.73 percent
Agenda item 8 62.15 percent
Agenda item 9a 67.13 percent
Agenda item 9b 67.13 percent
Agenda item 9c 67.15 percent
Agenda item 9d 67.13 percent
Agenda item 9e 67.13 percent
Agenda item 9f 67.13 percent
Agenda item 10 62.13 percent
Agenda item 11 62.12 percent

The invitation to the Annual General Meeting with details of the individual agenda items is available for download at https://www.cytotools.de/hauptversammlung.html. Approval ratings below 50.00 percent mean rejection of the agenda item, approval ratings above 50.00 percent mean adoption of the agenda item.

As a result of the dismissal of all Supervisory Board members, the current members of the Management Board of the Company are not available for an extension of their appointment to the Management Board, which ends today by rotation. Dr. Freyberg and Dr. Kaiser would like to expressly thank all shareholders for their many years of loyalty and support and remain closely associated with the Company as founders and shareholders.

Kontakt:
CytoTools AG
Klappacher Straße 126
64285 Darmstadt
Telefax: +49 6151 9515813
E-Mail: kontakt@cytotools.de


Über CytoTools:

Die CytoTools AG ist eine deutsche Biotechnologie Holding, die Ergebnisse aus der zellbiologischen Grundlagenforschung zu Zellwachstum und programmiertem Zelltod in neuartige Therapieformen zur ursächlichen Krankheitsbehandlung und Heilung umsetzt. CytoTools vielseitige Produktpipeline beinhaltet selbstentwickelte chemische Verbindungen und Biopharmazeutika, die das Potential haben, neue Behandlungsmöglichkeiten in der Dermatologie, Kardiologie, Urologie und Onkologie zu bieten. CytoTools ist als Technologieholding und Beteiligungsunternehmen strukturiert und hält Beteiligungen an den Tochterfirmen DermaTools Biotech GmbH (65 %) und CytoPharma GmbH (50 %).

Disclaimer

Diese Mitteilung enthält bestimmte in die Zukunft gerichtete Aussagen. Diese spiegeln die Meinung von CytoTools zum Datum dieser Mitteilung wider. Die von CytoTools tatsächlich erzielten Ergebnisse können von den Feststellungen in den zukunftsbezogenen Aussagen erheblich abweichen. CytoTools ist nicht verpflichtet, in die Zukunft gerichtete Aussagen zu aktualisieren.



30.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

IGEA Pharma N.V.

Original-Research: IGEA Pharma N.V. (von GBC AG): Kaufen

29. November 2021